Axsome Therapeutics Inc. (AXSM) Trading 2.3% Higher
Axsome Therapeutics Inc. (NASDAQ:AXSM)’s share price traded up 2.3% during trading on Tuesday . The company traded as high as $8.00 and last traded at $7.66, with a volume of 69,835 shares traded. The stock had previously closed at $7.49.
A number of equities analysts have recently commented on the company. Cantor Fitzgerald set a $13.00 price target on Axsome Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 10th. Zacks Investment Research raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 27th. Finally, Brean Capital reissued a “buy” rating on shares of Axsome Therapeutics in a report on Wednesday, August 10th.
The firm has a 50 day moving average price of $7.41 and a 200 day moving average price of $8.43. The stock’s market cap is $147.26 million.
A number of institutional investors have recently made changes to their positions in the stock. Teachers Advisors Inc. purchased a new position in shares of Axsome Therapeutics during the second quarter valued at $128,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Axsome Therapeutics during the second quarter valued at $134,000. Bank of New York Mellon Corp purchased a new position in shares of Axsome Therapeutics during the second quarter valued at $161,000. California State Teachers Retirement System purchased a new position in shares of Axsome Therapeutics during the second quarter valued at $176,000. Finally, BlackRock Investment Management LLC raised its position in shares of Axsome Therapeutics by 3,828.0% in the second quarter. BlackRock Investment Management LLC now owns 38,062 shares of the company’s stock valued at $287,000 after buying an additional 37,093 shares during the period. 30.30% of the stock is owned by institutional investors and hedge funds.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.